Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.

Abstract

BACKGROUND:

Parkinson's disease (PD) is characterized by a wide range of motor and non-motor symptoms. Levodopa is still the most effective drug; however, its long-term use is associated with motor complications which may deteriorate patient's quality of life. Safinamide is a unique treatment modulating both dopaminergic and glutamatergic systems. Previous results from two six months, double-blind, placebo-controlled studies demonstrated that safinamide has positive effects on both motor functions and quality of life in PD patients.

OBJECTIVE:

To investigate the effects of safinamide 100 mg/day over two-year treatment on PD symptoms severity and quality of life, using data from the study 018.

METHODS:

Data from 352 patients were analyzed to evaluate the effects of safinamide on OFF time and ON time (with no or non-troublesome dyskinesia) in the overall population and in subgroups of patients (receiving levodopa monotherapy or with other anti-Parkinson therapies), and the effects of safinamide on motor symptoms/clinical fluctuations (by means of UPDRS III and IV) and on health-related quality of life (using UPDRS II and PDQ-39 summary index score).

RESULTS:

Safinamide, administered as add-on to standard therapy in fluctuating PD patients, significantly improved motor symptoms and clinical fluctuations in the overall population and in some subgroups of patients. Additionally, safinamide improved quality of life and activities of daily living, maintaining the efficacy in the long-term.

CONCLUSIONS:

The findings of these analyses suggest that safinamide may be considered an appropriate adjunct therapy in patient not sufficiently controlled. Further investigations are desirable to confirm these results in usual care setting.

• Authors: Carlo Cattaneo, Wolfgang H Jost, Erminio Bonizzoni
• Journal: Journal of Parkinson's disease (J Parkinsons Dis) Vol. 10 Issue 1 Pg. 89-97 ( 2020) ISSN: 1877-718X [Electronic] Netherlands
• PMID: 31594253 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Antiparkinson Agents
• Benzylamines
• Monoamine Oxidase Inhibitors
• Glutamic Acid
• Levodopa
• safinamide
• Alanine

Topics

• Activities of Daily Living
• Aged
• Alanine (administration & dosage, analogs & derivatives, pharmacology)
• Antiparkinson Agents (administration & dosage, pharmacology)
• Benzylamines (administration & dosage, pharmacology)
• Double-Blind Method
• Drug Therapy, Combination
• Dyskinesias (drug therapy, etiology)
• Female
• Glutamic Acid
• Humans
• Levodopa (pharmacology)
• Male
• Middle Aged
• Monoamine Oxidase Inhibitors (administration & dosage, pharmacology)
• Outcome Assessment, Health Care
• Parkinson Disease (complications, drug therapy)
• Quality of Life
• Severity of Illness Index